Beta 2 adrenergic polymorphism detection

• US 6,593,092 B2
• Filed: 10/09/2001
• Issued: 07/15/2003
• Est. Priority Date: 04/04/2000
• Status: Expired due to Fees

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Yu, Hong, Merchant, Barbara T.
• Primary Examiner(s): Myers, Carla J.
• Assistant Examiner(s): JOHANNSEN, DIANA B
• Application Number:
  US09/973,132
• Publication Number:
  US 20020137069A1
• Time in Patent Office: 644 Days
• Field of Search: 435/6, 435/91.2, 435/810, 536/23.5, 536/24.31, 536/24.33
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6876 Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: Y10S 435/81 Packaged device or kit

Abstract

Nucleic acid sequences are provided that are useful as amplification primers, hybridization probes, and as a portion of molecular beacon probes for amplifying and detecting polymorphisms of the β2 adrenergic receptor gene, compositions and kits incorporating the same, and methods employing the same.

Claims

1. A composition comprising a molecular beacon probe for detecting a target sequence, the molecular beacon probe comprising a label moiety and a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO:

6, SEQ ID NO;

7, SEQ ID NO;

8, and SEQ ID NO;

9.

2. The composition of claim 1, wherein the molecular beacon probe comprises a label moiety and a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO:

6 and SEQ ID NO;

9.

3. The composition of claim 1, further comprising a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO 2, and SEQ ID NO 3.

4. A method for detecting a target sequence in a test sample comprising the steps of:

(a) forming a reaction mixture comprising nucleic acid amplification reagents, a nucleic acid having the nucleotide sequence designated SEQ ID NO;

2, a nucleic acid having the nucleotide sequence designated SEQ ID NO;

3, and a test sample suspected of containing a target sequence;

(b) subjecting the mixture to amplification conditions to generate an amplification product;

(c) contacting the amplification product with a molecular beacon probe comprising a label moiety and a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8 and SEQ ID NO;

9 such that in the presence of the target sequence the molecular beacon probe generates a signal; and

(d) detecting the signal generated by the beacon probe as an indication of the presence of the target sequence in the test sample.

5. The method of claim 4, wherein the molecular beacon probe therefore comprises a label moiety and a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO:

6, and SEQ ID NO;

9.

6. A kit for amplifying a β

2 adrenergic receptor target sequence comprising;

(a) a nucleic acid having the nucleotide sequence of SEQ ID NO;

2 and a nucleic acid having the nucleotide sequence of SEQ ID NO;

3;

(b) amplification reagents; and

(c) a molecular beacon probe comprising a label moiety and a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, and SEQ ID NO;

9.

7. The kit of claim 6, wherein the molecular beacon probe therefore comprises a label moiety and a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO:

6 and SEQ ID NO;

9.